Urinary beta-core hCG: Screening for aneuploidies in early pregnancy (11-14 weeks’ gestation).

MacIntosh, M. C. M., Nicolaides, K. H., Noble, P., Chard, Tim, Gunn, Lionel K. and Iles, Ray K. (1997) Urinary beta-core hCG: Screening for aneuploidies in early pregnancy (11-14 weeks’ gestation). Prenatal diagnosis, 17 (5) . pp. 401-405. ISSN 0197-3851 [Article] (doi:10.1002/(SICI)1097-0223(199705)17:5<401::AID-PD40>3.0.CO;2-M)

Abstract

Initial studies at 17-22 weeks' gestation evaluating urinary beta-core human chorionic gonadotrophin (hCG) as a marker for Down's syndrome had suggested that it may have more potential than its serum counterpart. This study measured maternal urinary beta-core-hCG and creatinine at 11-14 weeks' gestation in a series of 26 aneuploidies (nine trisomy 21, five trisomy 18, four 45,X0, and eight others). The normal range for beta-core-hCG and beta-core-hCG/creatinine was derived from 198 normal singleton pregnancies. Trisomy 18 cases (n=5) had low maternal urinary beta-core-hCG creatinine levels (median 0·35 MOM, range 0·08-0·82 MOM), whereas the other aneuploidies had no particular pattern; in particular, the trisomy 21 cases (n=9) (median 1·16 MOM, range 0·3-4·74 MOM) did not differ significantly from 1 MOM. The findings imply that maternal urinary beta-core-hCG is not as discriminating for Down's syndrome between 11 and 14 weeks as later on in pregnancy. © 1997 John Wiley & Sons, Ltd.

Actions (login required)

View Item

Statistics

DownloadsShow export options

Export as CSVXMLJSON

Activity Overview

6 month trend

0Downloads

6 month trend

415Hits

Additional statistics are available via IRStats2.